TEV - profilassi e terapia - Facolta' di Medicina e Chirurgia - Chieti

More documents

Recommendations

Info

Absolute Risk of DVT in Hospitalized Patients Geerts WH, et al. Chest 2004;126:338S–400S
Prophylaxis for VTE in Hospitalized Medical Patients • Anticoagulant prophylaxis with UFH or LMWH has been described as an efficacious, safe, and cost-effective intervention to prevent DVT in medical patients. • Furthermore, the American College of Chest Physicians Guidelines on Antithrombotic Therapy gives anticoagulant prophylaxis in medical patients a grade 1A recommendation. • Despite these considerations, anticoagulant prophylaxis in atrisk hospitalized medical patients is administered to only 16% to 33% of such patients , whereas up to 90% of at-risk surgical patients receive prophylaxis. Dentali F, et al. Ann Intern Med. 2007;146:278-288
Page 1 and 2: Facoltà di Medicina e Chirurgia Co
Page 3 and 4: Caratteristiche dei pazienti con tr
Page 5 and 6: Estrogen plus Progestin and Risk of
Page 7: Hazard Ratio di TV, TVP ed EP
Page 10 and 11: Razionale della tromboprofilassi in
Page 12 and 13: Razionale della tromboprofilassi in
Page 14 and 15: Grade 1A 1C+ 1B 1C Current Approach
Page 16 and 17: Livelli di rischio tromboembolico i
Page 21 and 22: Risk factors for VTE in Hospitalize
Page 23 and 24: Prevention of VTE in Hospitalized M
Page 25 and 26: Eparine Anticoagulanti Eparina stan
Page 27 and 28: • Relative: • Interventi chirur
Page 29 and 30: Eparina NF complicanze emorragiche
Page 31 and 32: HIT • Il rischio è lo stesso con
Page 33 and 34: Eparine a Basso Peso Molecolare (LM
Page 35 and 36: LMWH: specialità e dosaggi • Nad
Page 37 and 38: L’uso di aspirina da sola non è
Page 39 and 40: Prevenzione del tromboembolismo ven
Page 41 and 42: Raccomandiamo che pz sottoposti ad
Page 43 and 44: Fondaparinux Compared with Enoxapar
Page 45 and 46: Safety Outcomes Eriksson BI, et al.
Page 47 and 48: 12.5% vs 27.8% (P
Page 49 and 50: Frequency of venous thromboembolic
Page 51 and 52: Pz sottoposte ad interventoi gineco
Page 53 and 54: The PREVENT Thromboprophylaxis Stud
Page 55 and 56: Results: Efficacy (n=148) Enoxapari
Page 57 and 58: Pazienti di Terapia Intensiva Si ra
Page 59 and 60: Tromboembolismo venoso (TEV) Conclu
Page 61 and 62: Opzioni terapeutiche nel trattament
Page 63 and 64: La terapia dell’embolia polmonare
Page 65 and 66: Konstantinides S, et al. N Engl J M
Page 67 and 68: Reperti ecocardiografici tipici in
Page 69 and 70:
Eparina Antithrombin Thrombin Hepar
Page 71 and 72:
Terapia Approccio standard ENF 5.00
Page 73 and 74:
Terapia Approccio standard ENF 5.00
Page 75 and 76:
Warfarin: mechanism of action Higas
Page 77 and 78:
Problema della “finestra terapeut
Page 79 and 80:
TAO: modalità d’uso (II) •Dose
Page 81 and 82:
Durata ottimale dell’anticoagulaz
Page 83 and 84:
Long Long-Term, Term, Low Low-Inten
Page 85:
Comparison of low low-intensity int
Page 88 and 89:
Farmaci trombolitici • Farmaci ch
Page 90 and 91:
Terapia trombolitica: quando inizia
Page 92 and 93:
TPA: controindicazioni (I) • Asso
Page 94 and 95:
Valutazione efficacia rTPA vs Epari
Page 96 and 97:
Pazienti ad elevato rischio emorrag
Page 98 and 99:
Goldhaber SZ, Circulation 2003
Page 100 and 101:
Embolia Polmonare in gravidanza Inc
Page 102 and 103:
EP in gravidanza: terapia • Epari
Page 104 and 105:
TVP: impiego della contenzione elas
Page 106 and 107:
New anticoagulants ORAL PARENTERAL
Page 108 and 109:
Rivaroxaban www.xarelto.com/html/pr
show all

TEV - profilassi e terapia - Facolta' di Medicina e Chirurgia - Chieti

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?